BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 11533100)

  • 1. Impact of high-dose chemotherapy on peripheral T-cell lymphomas.
    Rodriguez J; Munsell M; Yazji S; Hagemeister FB; Younes A; Andersson B; Giralt S; Gajewski J; de Lima M; Couriel D; Romaguera J; Cabanillas FF; Champlin RE; Khouri IF
    J Clin Oncol; 2001 Sep; 19(17):3766-70. PubMed ID: 11533100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation.
    Kahl C; Leithäuser M; Wolff D; Steiner B; Hartung G; Casper J; Freund M
    Ann Hematol; 2002 Nov; 81(11):646-50. PubMed ID: 12454703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
    Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.
    Lewin J; Dickinson M; Voskoboynik M; Collins M; Ritchie D; Toner G
    Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
    Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C
    Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
    Rodríguez J; Conde E; Gutiérrez A; Arranz R; Gandarillas M; Leon A; Ojanguren J; Sureda A; Carrera D; Bendandi M; Moraleda J; Ribera JM; Albo C; Morales A; García JC; Fernández P; Cañigral G; Bergua J; Caballero MD;
    Eur J Haematol; 2007 Apr; 78(4):290-6. PubMed ID: 17378891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
    Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
    J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
    Gao Y; Huang HQ; Lin XB; Cai QQ; Pan ZH; Wang BF; Bu Q
    Ai Zheng; 2007 Aug; 26(8):909-13. PubMed ID: 17697558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
    Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
    Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
    Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
    Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.
    Prochazka V; Faber E; Raida L; Vondrakova J; Kucerova L; Jarosova M; Indrak K; Papajik T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):63-6. PubMed ID: 19365529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study.
    Feyler S; Prince HM; Pearce R; Towlson K; Nivison-Smith I; Schey S; Gibson J; Patton N; Bradstock K; Marks DI; Cook G
    Bone Marrow Transplant; 2007 Sep; 40(5):443-50. PubMed ID: 17589529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.
    Blystad AK; Enblad G; Kvaløy S; Berglund A; Delabie J; Holte H; Carlson K; Kvalheim G; Bengtsson M; Hagberg H
    Bone Marrow Transplant; 2001 Apr; 27(7):711-6. PubMed ID: 11360110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation.
    Schetelig J; Fetscher S; Reichle A; Berdel WE; Beguin Y; Brunet S; Caballero D; Majolino I; Hagberg H; Johnsen HE; Kimby E; Montserrat E; Stewart D; Copplestone A; Rösler W; Pavel J; Kingreen D; Siegert W
    Haematologica; 2003 Nov; 88(11):1272-8. PubMed ID: 14607756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
    Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
    Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
    Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
    Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission.
    Mehta N; Maragulia JC; Moskowitz A; Hamlin PA; Lunning MA; Moskowitz CH; Zelenetz A; Matasar MJ; Sauter C; Goldberg J; Horwitz SM
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):664-70. PubMed ID: 24035712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma.
    Rodríguez J; Conde E; Gutiérrez A; Lahuerta JJ; Arranz R; Sureda A; Zuazu J; Fernández de Sevilla A; Bendandi M; Solano C; León A; Varela MR; Caballero MD;
    Haematologica; 2007 Aug; 92(8):1067-74. PubMed ID: 17640855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience.
    Rohlfing S; Dietrich S; Witzens-Harig M; Hegenbart U; Schönland S; Luft T; Ho AD; Dreger P
    Ann Hematol; 2018 Jul; 97(7):1241-1250. PubMed ID: 29549411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
    Gkotzamanidou M; Papadimitriou CA
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.